In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM.
Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study
Frittitta L.Membro del Collaboration Group
;Piro S.;
2019-01-01
Abstract
In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Fadini2019_Article_PredictorsOfEarlyDiscontinuati.pdf
solo gestori archivio
Descrizione: articolo principale
Tipologia:
Documento in Post-print
Dimensione
581.57 kB
Formato
Adobe PDF
|
581.57 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
